Ares Life Sciences invests CHF 15.9 million in Santhera in a PIPE transaction

Lenz & Staehelin advised Ares Life Sciences, an investment vehicle established by the Bertarelli family, in connection with an acquisition of newly issued shares of Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company focused on neuromuscular diseases, for a gross amount of CHF 15.9 million. The new shares where sold to Ares Life Sciences within the framework of a private placement, and represented about 10.6% of the share capital and voting rights of the company.

The team was led by Jacques Iffland and David Ledermann, and included Leila Hawa, Jérôme Jotterand and Hélène Weidmann.